Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Fox04-DRI: Evidence Summary
Evidence summary for Fox04-DRI across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to Fox04-DRI overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Senolytic therapy | Tier D | 0 | Disrupts FOXO4-p53 interaction to induce senescent cell apoptosis; mouse data only |
| Anti-aging | Tier D | 0 | Restored fitness and fur density in aged mice; no human trials initiated |
References (6)
- FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice. . Naunyn-Schmiedeberg's archives of pharmacology (2023) PMID: 37074394
- FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway. . Journal of cellular and molecular medicine (2022) PMID: 35510614
- Targeting senescence-like fibroblasts radiosensitizes non-small cell lung cancer and reduces radiation-induced pulmonary fibrosis. . JCI insight (2021) PMID: 34877934
- FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. . Aging (2020) PMID: 31959736
- Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. — Baar MP, Brandt RMC, Putavet DA, et al. . Cell (2017) PMID: 28340339
- Molecular regulative mechanisms of aging and interventional effects of Chinese herbal medicine. . Zhongguo Zhong yao za zhi (2017) PMID: 29171222